On behalf of our chairmen James O. Armitage, MD, and Franco Cavalli, MD, FRCP, we are pleased to welcome you to the our symposium “Challenges, Controversies, and Opportunities in Non-Hodgkin Lymphoma” during the Educational Cancer Convention Lugano – What Is New in Haemato-Oncology? in Lugano, Switzerland, on 18 April 2010.
During this case-based meeting, leaders in the field discuss with participants, in an interactive format, clinical issues encountered daily by practicing physicians.
Faculty
Untitled Document
Co-Chairs:
James O. Armitage, MD
Department of Oncology and Hematology
University of Nebraska Medical Center
Omaha, United States
Franco Cavalli, MD, FRCP
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
Faculty:
Michele Ghielmini, MD
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
Gilles Salles, MD, PhD
Department of Haematology
Centre Hospitalier Lyon Sud
Lyon Pierre Benite, France
Martin Dreyling, MD, PhD
University Hospital Grosshadern
Munich, Germany
Pier Luigi Zinzani, MD, PhD
Institute of hematology and oncology L. & A. Seragnoli
University of Bologna
Bologna, Italy
Agenda
Untitled Document
* Lunch will be served during the activity
13.15
Welcome and introduction James O. Armitage, MD
Franco Cavalli, MD, FRCP
13.20
The 2009 Pan Pacific Lymphoma Conference: Overview and history James O. Armitage, MD
13.30
Interactive Debate #1
Conservative or aggressive therapy for mantle-cell lymphoma Michele Ghielmini, MD versus Martin H. Dreyling, MD, PhD
14.00
Rituximab maintenance for follicular lymphoma: Current state of the art Gilles Salles, MD, PhD
14.30
Interactive Debate #2
Peripheral T-cell lymphoma: What is the best therapeutic strategy and when should transplantation be utilized? Pier Luigi Zinzani, MD, PhD versus James O. Armitage, MD
15.00
Panel Discussion
Pearls and pitfalls in lymphoma management: Lessons from Pan Pacific 2009 All faculty
1. What is the role of imaging studies in patients who achieve a CR?
2. Does radiotherapy have a role in DLBCL?
3. What is the best induction regimen for advanced DLBCL?
4. Which prognostic markers should be used in treating CLL/SLL?
5. What are the current indications for allogeneic stem cell transplantation in NHL?
6. What is the current role of “functional imaging” in lymphoma management?
15.30
Closing remarks and adjournment James O. Armitage, MD
Franco Cavalli, MD, FRCP
This activity is part of the larger ECCLU congress, which has been certified with 10 European CME by ACOE and UEMS and has been accredited with 11 ESMO-MORA category 1 points.
